Cathy Zhao

ORCID: 0000-0003-4722-9673
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Autoimmune Bullous Skin Diseases
  • Dermatology and Skin Diseases
  • Allergic Rhinitis and Sensitization
  • Coagulation, Bradykinin, Polyphosphates, and Angioedema
  • Urticaria and Related Conditions
  • Schizophrenia research and treatment
  • Asthma and respiratory diseases
  • Lymphoma Diagnosis and Treatment
  • Glaucoma and retinal disorders
  • Advanced Glycation End Products research
  • Bipolar Disorder and Treatment
  • Ocular Surface and Contact Lens
  • Autoimmune and Inflammatory Disorders
  • Cutaneous Melanoma Detection and Management
  • Melanoma and MAPK Pathways
  • Cancer Immunotherapy and Biomarkers
  • Eosinophilic Disorders and Syndromes
  • Immune Response and Inflammation
  • Cutaneous lymphoproliferative disorders research
  • Nail Diseases and Treatments
  • Chemotherapy-related skin toxicity
  • Mobile Health and mHealth Applications
  • Mental Health and Psychiatry
  • Nonmelanoma Skin Cancer Studies
  • Mental Health Research Topics

AbbVie (United States)
2023-2024

Allergan (United States)
2023-2024

St George Hospital
2015-2024

UNSW Sydney
2015-2024

Shandong Provincial Hospital
2024

Shandong First Medical University
2024

The University of Sydney
2012-2023

Royal North Shore Hospital
2021-2022

Westmead Hospital
2017-2022

Concord Repatriation General Hospital
2021

Abstract Objective There is a need for comparative studies to provide evidence‐based treatment guidance biologic agents in rheumatoid arthritis (RA). Therefore, this study was undertaken as the first head‐to‐head comparison of subcutaneous (SC) abatacept and SC adalimumab, both administered along with background methotrexate (MTX), RA. Methods Patients active RA who were naive had an inadequate response MTX randomly assigned receive 125 mg weekly or 40 adalimumab biweekly, given combination...

10.1002/art.37711 article EN Arthritis & Rheumatism 2012-11-20

Toll like receptor (TLR) 4 has been reported to promote inflammation in diabetic nephropathy. However the role of TLR4 complicated pathophysiology nephropathy is not understood. In this study, we report elevated expression TLR4, its endogenous ligands and downstream cytokines, chemokines fibrogenic genes WT mice with streptozotocin (STZ) diabetes. Subsequently, demonstrated that TLR4−/− were protected against development nephropathy, exhibiting less albuminuria, inflammation, glomerular...

10.1371/journal.pone.0097985 article EN cc-by PLoS ONE 2014-05-19

This article is a report of the fourth meeting Harmonising Outcome Measures for Eczema (HOME) initiative held in Malmö, Sweden on 23–24 April 2015 (HOME IV). The aim was to achieve consensus over preferred outcome instruments measuring patient‐reported symptoms and quality life HOME core set atopic eczema (AE). Following presentations, which included data from systematic reviews, discussions were mixture whole group small discussions. Small groups allocated priori ensure representation...

10.1111/bjd.14773 article EN cc-by-nc British Journal of Dermatology 2016-07-01

Peripheral leukocytes in patients with atopic dermatitis (AD) have elevated phosphodiesterase-4 activity, which is associated production of proinflammatory mediators. OPA-15406 a inhibitor high selectivity for phosphodiesterase-4-B.We sought to assess effectiveness and tolerability topical AD.This was randomized, double-blind, vehicle-controlled, phase-II study. Patients 10 70 years age mild or moderate AD received 0.3% (n = 41), 1% 43), vehicle 37) twice daily 8 weeks.The primary end point,...

10.1016/j.jaad.2016.04.001 article EN cc-by-nc-nd Journal of the American Academy of Dermatology 2016-05-14

Adherence to topical corticosteroids (TCS) is essential for the effective treatment of atopic dermatitis but can be limited by concerns about their use. This study examined feasibility applying validated TOPICOP score assessing TCS phobia across different countries.This was a prospective multicentre conducted in 21 hospitals 17 countries. Patients >3 months age with or parents legal representatives completed translation questionnaire country's native language. Respondents also questionnaires...

10.1111/all.13189 article EN Allergy 2017-04-25

Aliskiren is a novel, orally active direct renin inhibitor that lowers blood pressure alone and in combination with existing antihypertensive agents. As aliskiren does not affect cytochrome P450 enzyme activities, minimally metabolised, extensively protein bound, the potential for drug interactions predicted to be low. Four open-label studies investigated pharmacokinetic between 300 mg drugs amlodipine 10 (n = 18), valsartan 320 hydrochlorothiazide 25 (HCTZ, n 22) ramipril 17) healthy...

10.1111/j.1742-1241.2006.01164.x article EN International Journal of Clinical Practice 2006-10-11

Toll-like receptors (TLRs) play a fundamental role in innate immunity and provide link between adaptive responses to an allograft; however, whether the development of acute chronic allograft rejection requires TLR signaling is unknown. Here, we studied fully MHC-mismatched, life-sustaining murine model kidney rejection. Mice deficient adaptor protein MyD88 developed donor antigen-specific tolerance, which protected them from both increased their survival after transplantation compared with...

10.1681/asn.2012010052 article EN Journal of the American Society of Nephrology 2012-08-12

Atopic dermatitis (AD) assessment is more difficult in patients with skin of colour (SOC).To compare the reliability commonly used outcome measures for assessing AD SOC and to evaluate a novel greyscale this population.Twenty-five each attended 1-day scoring exercise based either Sydney or Melbourne, Australia. Each patient was scored by same five physicians using Eczema Area Severity Index (EASI), objective Scoring Dermatitis (oSCORAD), Investigator's Global Assessment (IGA) greyscale....

10.1111/bjd.15271 article EN British Journal of Dermatology 2016-12-25

To compare hospitalization rates in patients with schizophrenia treated prospectively aripiprazole once-monthly 400 mg (AOM 400; an extended-release injectable suspension) vs the same patients' retrospective their prior oral anti-psychotic therapy.Multi-center, open-label, mirror-image, naturalistic study a community setting North America. Patients who required change treatment and/or would benefit from long-acting therapy were for 6 months AOM 400. Retrospective data on...

10.3111/13696998.2014.979936 article EN Journal of Medical Economics 2014-10-27

Background The prevalence of mental disorders among young and middle-aged populations has demonstrated a significant upward trend, with first-episode psychosis (FEP) frequently associated psychological distress functional impairments during initial onset. While persons affected by FEP report reduced quality life early illness stages, they may also experience post-traumatic growth (PTG), which fosters positive changes that facilitate their recovery. Yet there is limited attention on PTG in...

10.3389/fpsyt.2025.1538275 article EN cc-by Frontiers in Psychiatry 2025-04-29

Outcome measures for atopic dermatitis (AD) patients with pigmented skin have neither been developed nor validated. To compare the reliability and validity of four common AD outcome in various levels darkness. The inter- intra-rater construct EASI (Eczema Area Severity Index), objective-SCORing Atopic Dermatitis (oSCORAD), Three Items index (TIS) Six Areas, Sites (SASSAD) were evaluated 18 darkness, using their full body photographs, by five trained clinicians. inter-rater intraclass...

10.1016/j.ijwd.2015.05.002 article EN cc-by-nc-nd International Journal of Women’s Dermatology 2015-08-01

Background There are multiple severity outcome measures for atopic dermatitis (AD). is a need to compare the reliability of these measures. Objectives To inter-rater and intrarater objective Scoring Atopic Dermatitis (oSCORAD), Eczema Area Severity Index (EASI), Six Area, Sign (SASSAD) Three Item index (TIS); analyse correlation between quality-of-life instruments Patient-Orientated Measurement, Dermatology Life Quality Skindex-29. Methods Twelve patients with AD attended 1-day scoring...

10.1111/bjd.13846 article EN British Journal of Dermatology 2015-04-18

Purpose: Information on the relationship between meibum lipid composition and severity of meibomian gland dysfunction (MGD) is limited. The purpose this study was to analyze molecular components collected from individuals with no MGD, mild-to-moderate severe MGD. Methods: Adults without MGD were enrolled in a prospective, multicenter, exploratory clinical trial (ClinicalTrials.gov Identifier: NCT01979887). Molar ratios cholesteryl ester wax (RCE/WE) aldehyde (Rald/WE) samples measured 1H-NMR...

10.1167/iovs.64.10.22 article EN cc-by-nc-nd Investigative Ophthalmology & Visual Science 2023-07-19

Purpose: Changes in meibum composition and quantity meibomian gland dysfunction (MGD) result tear film instability dry eye. This exploratory study aimed to identify changes (O-acyl)-ω-hydroxy fatty acid (OAHFA) hydrocarbon chain (HC) unsaturation levels related the presence severity of MGD.

10.1089/jop.2024.0063 article EN Journal of Ocular Pharmacology and Therapeutics 2024-08-16

Nonadherence to medication compromises the effectiveness of psychiatric treatments in patients with serious mental illness (SMI). A newly developed digital medicine system (DMS) offers an opportunity objectively assess and report patient adherence. DMS includes a wearable sensor that receives data signal from tablet embedded ingestible after ingestion transmits patient's mobile device display health care information for treatment team.Development requires program investigates safety,...

10.4088/jcp.16m10693 article EN The Journal of Clinical Psychiatry 2016-07-29

Medication nonadherence is common in the treatment of serious mental illness (SMI) and leads to poor outcomes. The digital medicine system (DMS) objectively measures adherence with oral aripiprazole near-real time, allowing recognition issues. This pilot study evaluated functionality an integrated call center optimizing use DMS.An 8-week, open-label, single-arm trial at four US sites enrolled adults bipolar I disorder, major depressive schizophrenia on stable doses willing DMS (oral +...

10.2147/ndt.s143091 article EN cc-by-nc Neuropsychiatric Disease and Treatment 2017-10-01

Article AbstractBackground: A digital medicine system (DMS) has been developed to measure and report adherence an atypical antipsychotic, aripiprazole, in psychiatric patients. The DMS consists of 3 components: ingestible sensor embedded a medication tablet, wearable sensor, secure mobile cloud-based applications. An umbrella study protocol was designed rapidly assess the technical performance safety multiple substudies guide technology development.Methods: Two sequential enrolled 30 29...

10.4088/jcp.16m10643 article EN The Journal of Clinical Psychiatry 2016-07-01
Coming Soon ...